RCAG
LUMO

Rehmann Capital Advisory Group’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Rehmann Capital Advisory Group’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-22
Closed -$962 – 2197
2018
Q2 		$962 Buy
+22
New +$1.01K ﹤0.01% 1978

Other funds holding LUMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rehmann Capital Advisory Group's LUMO Position: Q3 2018 in Review

Rehmann Capital Advisory Group sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2018, closing a stake of 22 shares — an estimated $962 sold.

Rehmann Capital Advisory Group first reported a position in LUMO in Q2 2018 and held it in 1 quarter. The position peaked at $962 in Q2 2018. 92 funds tracked by Wall St. Rank hold LUMO as of Q3 2018.

  • Rehmann Capital Advisory Group reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 22 Lumos Pharma, Inc. Common Stock shares in Q3 2018, an estimated $962.
  • Rehmann Capital Advisory Group first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Rehmann Capital Advisory Group's Lumos Pharma, Inc. Common Stock position peaked at $962 in Q2 2018.
  • 92 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2018.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2018, filed 20 Nov 2018.